Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 AUD | -5.74% | -5.35% | -20.42% |
03-05 | Australia shares inch lower as miners weigh; GDP data in focus | RE |
02-28 | Australian Clinical Labs Falls 11% After Trimming Interim Dividend on Lower H1 FY24 EPS | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.42% | 327M | C | ||
+19.19% | 84.52B | C+ | ||
-27.44% | 72.21B | B- | ||
+4.65% | 27.74B | C+ | ||
-8.00% | 17.97B | B | ||
-0.46% | 17.46B | A- | ||
+3.76% | 15.82B | A- | ||
+7.89% | 13.55B | B- | ||
+6.59% | 13.31B | A- | ||
+70.12% | 12.5B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACL Stock
- Ratings Australian Clinical Labs Limited